Table 2. Investigator-Reported Best Overall Responseto Alvocidib in the ITT Population.

	Hybrid Criteria^a		NCI-96 Criteria^b
	Number	Percent	Number	Percent
Overall Response Rate	41	25	50	30
Complete Response	3	2	6	4
Nodular Partial Response (nPR)	2	1	2	1
Partial Response	36	22	42	26
Stable Disease	53	32	66	40
Disease Progression	21	13	26	16
Not assessed	50^a	30	23^b	14
del(17p) (n = 49)	7	14	13	27
del(11q) (n = 43)^c	11	26	12	28
Bulky lymphadenopathy (n = 115)	29	25	33	29
“Double refractory”^d (n = 48)	5	10	7	15
TLS (n = 39)	12	31	15	38

Of the 50 patients not assessed for best response, 6 were never treated with alvocidib and 28 receivedonly one treatment cycle. The remaining 16 patients received between 2 and 6 cycles of treatment, but the investigator failed to report a best response by hybrid criteria. No missing data imputation was performed.

Of the 23 patients who were not assessed for best response, 6 were never treated with alvocidib and 14 had only one treatment cycle. The remaining 3 patients received 2 or 3 cycles of treatment, but the investigator failed to report a best response by NCI 96 criteria. No missing data imputation was performed.

Classified according to Döhner, et al³¹.

Refractory to both fludarabine and alemtuzumab